Cargando…

The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)

BACKGROUND: The most common type of monogenic diabetes is maturity-onset diabetes of the young (MODY), a clinically and genetically heterogeneous group of endocrine disorders that affect 1–5% of all patients with diabetes mellitus. MODY is characterized by autosomal dominant inheritance but de novo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nkonge, Ken Munene, Nkonge, Dennis Karani, Nkonge, Teresa Njeri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640483/
https://www.ncbi.nlm.nih.gov/pubmed/33292863
http://dx.doi.org/10.1186/s40842-020-00112-5
_version_ 1783605755480375296
author Nkonge, Ken Munene
Nkonge, Dennis Karani
Nkonge, Teresa Njeri
author_facet Nkonge, Ken Munene
Nkonge, Dennis Karani
Nkonge, Teresa Njeri
author_sort Nkonge, Ken Munene
collection PubMed
description BACKGROUND: The most common type of monogenic diabetes is maturity-onset diabetes of the young (MODY), a clinically and genetically heterogeneous group of endocrine disorders that affect 1–5% of all patients with diabetes mellitus. MODY is characterized by autosomal dominant inheritance but de novo mutations have been reported. Clinical features of MODY include young-onset hyperglycemia, evidence of residual pancreatic function, and lack of beta cell autoimmunity or insulin resistance. Glucose-lowering medications are the main treatment options for MODY. The growing recognition of the clinical and public health significance of MODY by clinicians, researchers, and governments may lead to improved screening and diagnostic practices. Consequently, this review article aims to discuss the epidemiology, pathogenesis, diagnosis, and treatment of MODY based on relevant literature published from 1975 to 2020. MAIN BODY: The estimated prevalence of MODY from European cohorts is 1 per 10,000 in adults and 1 per 23,000 in children. Since little is known about the prevalence of MODY in African, Asian, South American, and Middle Eastern populations, further research in non-European cohorts is needed to help elucidate MODY’s exact prevalence. Currently, 14 distinct subtypes of MODY can be diagnosed through clinical assessment and genetic analysis. Various genetic mutations and disease mechanisms contribute to the pathogenesis of MODY. Management of MODY is subtype-specific and includes diet, oral antidiabetic drugs, or insulin. CONCLUSIONS: Incidence and prevalence estimates for MODY are derived from epidemiologic studies of young people with diabetes who live in Europe, Australia, and North America. Mechanisms involved in the pathogenesis of MODY include defective transcriptional regulation, abnormal metabolic enzymes, protein misfolding, dysfunctional ion channels, or impaired signal transduction. Clinicians should understand the epidemiology and pathogenesis of MODY because such knowledge is crucial for accurate diagnosis, individualized patient management, and screening of family members.
format Online
Article
Text
id pubmed-7640483
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76404832020-11-04 The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY) Nkonge, Ken Munene Nkonge, Dennis Karani Nkonge, Teresa Njeri Clin Diabetes Endocrinol Review Article BACKGROUND: The most common type of monogenic diabetes is maturity-onset diabetes of the young (MODY), a clinically and genetically heterogeneous group of endocrine disorders that affect 1–5% of all patients with diabetes mellitus. MODY is characterized by autosomal dominant inheritance but de novo mutations have been reported. Clinical features of MODY include young-onset hyperglycemia, evidence of residual pancreatic function, and lack of beta cell autoimmunity or insulin resistance. Glucose-lowering medications are the main treatment options for MODY. The growing recognition of the clinical and public health significance of MODY by clinicians, researchers, and governments may lead to improved screening and diagnostic practices. Consequently, this review article aims to discuss the epidemiology, pathogenesis, diagnosis, and treatment of MODY based on relevant literature published from 1975 to 2020. MAIN BODY: The estimated prevalence of MODY from European cohorts is 1 per 10,000 in adults and 1 per 23,000 in children. Since little is known about the prevalence of MODY in African, Asian, South American, and Middle Eastern populations, further research in non-European cohorts is needed to help elucidate MODY’s exact prevalence. Currently, 14 distinct subtypes of MODY can be diagnosed through clinical assessment and genetic analysis. Various genetic mutations and disease mechanisms contribute to the pathogenesis of MODY. Management of MODY is subtype-specific and includes diet, oral antidiabetic drugs, or insulin. CONCLUSIONS: Incidence and prevalence estimates for MODY are derived from epidemiologic studies of young people with diabetes who live in Europe, Australia, and North America. Mechanisms involved in the pathogenesis of MODY include defective transcriptional regulation, abnormal metabolic enzymes, protein misfolding, dysfunctional ion channels, or impaired signal transduction. Clinicians should understand the epidemiology and pathogenesis of MODY because such knowledge is crucial for accurate diagnosis, individualized patient management, and screening of family members. BioMed Central 2020-11-04 /pmc/articles/PMC7640483/ /pubmed/33292863 http://dx.doi.org/10.1186/s40842-020-00112-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review Article
Nkonge, Ken Munene
Nkonge, Dennis Karani
Nkonge, Teresa Njeri
The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)
title The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)
title_full The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)
title_fullStr The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)
title_full_unstemmed The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)
title_short The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)
title_sort epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (mody)
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640483/
https://www.ncbi.nlm.nih.gov/pubmed/33292863
http://dx.doi.org/10.1186/s40842-020-00112-5
work_keys_str_mv AT nkongekenmunene theepidemiologymolecularpathogenesisdiagnosisandtreatmentofmaturityonsetdiabetesoftheyoungmody
AT nkongedenniskarani theepidemiologymolecularpathogenesisdiagnosisandtreatmentofmaturityonsetdiabetesoftheyoungmody
AT nkongeteresanjeri theepidemiologymolecularpathogenesisdiagnosisandtreatmentofmaturityonsetdiabetesoftheyoungmody
AT nkongekenmunene epidemiologymolecularpathogenesisdiagnosisandtreatmentofmaturityonsetdiabetesoftheyoungmody
AT nkongedenniskarani epidemiologymolecularpathogenesisdiagnosisandtreatmentofmaturityonsetdiabetesoftheyoungmody
AT nkongeteresanjeri epidemiologymolecularpathogenesisdiagnosisandtreatmentofmaturityonsetdiabetesoftheyoungmody